• Basilea Pharmaceutica secures $6M non‑dilutive grant from CARB‑X for novel antibiotic BAL2420
Basilea - Latest News and Information
  • All Technology
  • AI
  • Autonomy
  • B2B Growth
  • Big Data
  • BioTech
  • ClimateTech
  • Consumer Tech
  • Cybersecurity
  • DevOps
  • Digital Marketing
  • Ecommerce
  • EdTech
  • Enterprise
  • FinTech
  • GovTech
  • Hardware
  • HealthTech
  • HRTech
  • LegalTech
  • Nanotech
  • PropTech
  • Quantum
  • Robotics
  • SaaS
  • SpaceTech
AllNewsDealsSocialBlogsVideosPodcastsDigests

Technology Pulse

EMAIL DIGESTS

Daily

Every morning

Weekly

Tuesday recap

Top Publishers

  • The Verge AI

    The Verge AI

    21 followers

  • TechCrunch AI

    TechCrunch AI

    19 followers

  • Crunchbase News AI

    Crunchbase News AI

    15 followers

  • TechRadar

    TechRadar

    15 followers

  • Hacker News

    Hacker News

    13 followers

See More →

Top Creators

  • Ryan Allis

    Ryan Allis

    217 followers

  • Elon Musk

    Elon Musk

    82 followers

  • Sam Altman

    Sam Altman

    68 followers

  • Mark Cuban

    Mark Cuban

    59 followers

  • Jack Dorsey

    Jack Dorsey

    40 followers

See More →

Top Companies

  • SaasRise

    SaasRise

    219 followers

  • Anthropic

    Anthropic

    40 followers

  • OpenAI

    OpenAI

    22 followers

  • Hugging Face

    Hugging Face

    15 followers

  • xAI

    xAI

    12 followers

See More →

Top Investors

  • Andreessen Horowitz

    Andreessen Horowitz

    16 followers

  • Y Combinator

    Y Combinator

    15 followers

  • Sequoia Capital

    Sequoia Capital

    12 followers

  • General Catalyst

    General Catalyst

    8 followers

  • A16Z Crypto

    A16Z Crypto

    5 followers

See More →
NewsDealsSocialBlogsVideosPodcasts
HomeBasilea
Basilea logo

Basilea

0 followers

BSLN

Performance

About Basilea

Basilea Pharmaceutica Ltd. is a Basel-area biopharmaceutical company focused on developing and commercializing innovative anti-infective medicines to address severe bacterial and fungal infections. The company emphasizes research and global commercialization of therapies in areas such as antifungal and antibacterial treatments. Based in Allschwil near Basel, Switzerland, Basilea is listed on the SIX Swiss Exchange and collaborates on partnerships and investor activities to advance its portfolio and pipeline for patients worldwide.

Recent News

No recent news for this company.

Recent Deals

Basilea Pharmaceutica Secures $6M Non‑dilutive Grant From CARB‑X for Novel Antibiotic BAL2420

April 9, 2026

Key Team Members

Marc Engelhardt, M.D.

Chief Medical Officer

Gerrit Hauck, Ph.D.

Chief Technology Officer

Laurenz Kellenberger, Ph.D.

Chief Scientific Officer

Adesh Kaul

Chief Financial Officer

David Veitch

Chief Executive Officer

Key Facts

HQ Location

Allschwil, Switzerland

Founded

2000

Employees

201 - 500

Status

Public

Website

https://basilea.com